Satoshi's TAKE-TWO: New blockchain protocol poised to bring digital currency to the masses
mehr
Storys zum Thema Wirtschaft
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Security of supply and politics - a conflict? / Third national Swiss Medtech MDR&IVDR Conference
mehrBempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
mehrEANS-Adhoc: ams AG / ams announces achievement of maximum share repurchase volume under and completion of current share repurchase program
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: English ...
mehrMartini Racing Ciclismo: Tom Boonen Appointed as Road Captain
Brussels (ots/PRNewswire) - Tom Boonen is back in the peloton, albeit a so-called "horecapeloton." Martini Racing Ciclismo will be made up of participants from the HOtel, REstaurant and CAtering sector. Former world champion, three times winner of the Ronde Van Vlaanderen and four times winner of the Paris-Roubaix classic, Boonen has now taken on the role of Road Captain in support of a project aiming to get workers in ...
mehrFDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...
mehrForaCare Suisse AG Distributor, AlphaDiab, Ranked One of the Fastest Growing Companies in France
ST. GALLEN, Switzerland, (ots) - ForaCare Suisse AG (ForaCare, FORA) announced its distributor, AlphaDiab was recently named by Les Echos and Statista as one of the top fastest growing companies in France. With an average annual growth rate of 46 percent and an increase between 2014 and 2017 of 212 percent, ...
mehrMicreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...
mehrCybersecurity Spend Tops US$10 Billion in Q4 2018 as New Deployment Models Gain Traction
Palo Alto, California, Shanghai, Singapore and Reading, England (ots/PRNewswire) - According to Canalys estimates, worldwide cybersecurity spending exceeded US$10 billion for the first time in Q4 2018. Organizations increased their level of protection against malicious threats, while adhering to strengthening data compliance regulations. Total cybersecurity investment ...
mehrMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...
mehrMountain Rescue Study Launches to Investigate Use of Penthrox® (Methoxyflurane) for Trauma-related Pain in Hostile Environments
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
mehrEANS-News: ANDRITZ AG Annual General Meeting approves dividend of 1.55 euros per share
issuer: Andritz AG Stattegger Straße 18 A-8045 Graz phone: +43 (0)316 6902-0 FAX: +43 (0)316 6902-415 mail: welcome@andritz.com WWW: www.andritz.com ISIN: AT0000730007 indexes: ATX, WBI stockmarkets: Wien language: English ...
mehrMallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
mehrShortlist European Press Prize 2019
Amsterdam (ots/PRNewswire) - This is the shortlist for the European Press Prize 2019. The winners will be announced on May 23rd at Gazeta Wyborcza in Warsaw. Learn more about the prize here (http://europeanpressprize.com/). Distinguished Reporting - '56 days' - Katrin Kuntz, Marian Blasberg, Christoph Scheuermann, Der Spiegel (Germany) - 'Gaza. It's time for change' - Francesca Borri, Yedioth Ahronoth (Israel) & La ...
mehrMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
mehrMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
mehrOral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
mehrEANS-News: Semperit AG Holding / Significant improvement in operating earnings in 2018 ? particularly due to Industrial sector ? downward trend stopped
issuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wien phone: +43 1 79 777-210 FAX: +43 1 79 777-602 mail: stefan.marin@semperitgroup.com WWW: www.semperitgroup.com ISIN: AT0000785555 indexes: ATX PRIME, WBI, ATX GP stockmarkets: Wien language: English ...
mehrGenePOC obtains FDA clearance for its GenePOC(TM) Strep A test in the US
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
mehrEANS-Adhoc: European Lithium Limited / Statement on OTS Announcement by Mag. Josef Wallner, Mayor of the Municipality of Deutschlandsberg from March, 20th 2019
issuer: European Lithium Limited 32 Harrogate Street A-WA6007 West Leederville phone: FAX: mail: katharina.loeckinger@europeanlithium.com WWW: www.europeanlithium.com ISIN: AU000000EUR7 indexes: stockmarkets: Frankfurt, Wien language: English ...
mehrHostpoint exceeds CHF 20 million in turnover
mehrRenault-Nissan-Mitsubishi Launches Alliance Intelligent Cloud on Microsoft Azure
Paris, Tokyo and Yokohama, Japan (ots/PRNewswire) - - Alliance Intelligent Cloud built on Microsoft Azure to power the Alliance's latest connected services - World's leading automotive alliance to use Alliance Intelligent Cloud for connected infrastructure in nearly all 200 markets served by Renault, Nissan and Mitsubishi - Alliance Intelligent Cloud to power the ...
mehrPrimex Pharmaceuticals and Nordic Group Sign a Strategic Partnership to Commercialise OZALIN® in France
Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...
mehrMerck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
mehrData from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
mehrEANS-News: AGRANA opens new fruit preparations plant in Changzhou (China) - IMAGE
http://resources.euroadhoc.com/images/2118/5/10276822/Eröffnung_Changzhou.jpg http://resources.euroadhoc.com/images/2118/5/10276822/Eröffnung_Changzhou2.jpg issuer: AGRANA Beteiligungs-AG F.-W.-Raiffeisen-Platz 1 A-1020 Wien phone: +43-1-21137-0 FAX: +43-1-21137-12926 mail: info.ab@agrana.com WWW: www.agrana.com ISIN: AT000AGRANA3 indexes: WBI stockmarkets: Wien, ...
mehrCLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
mehrNyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and ...
mehrSCHOELLER-BLECKMANN OILFIELD EQUIPMENT Aktiengesellschaft
EANS-News: Schoeller-Bleckmann Oilfield Equipment AG posts significant increase in earnings in 2018 - ATTACHMENT
http://resources.euroadhoc.com/documents/226/5/10279731/1/190311-CGB-A4-EN.pdf http://resources.euroadhoc.com/documents/226/5/10279731/1/190311-Geschäftsbericht-EN-A4.pdf issuer: Schoeller-Bleckmann Oilfield Equipment AG Hauptstrasse 2 A-2630 Ternitz phone: 02630/315110 FAX: 02630/315101 mail: sboe@sbo.co.at WWW: ...
mehrEANS-Adhoc: ams AG / ams and Wise Road Capital advance further development for environmental, flow and pressure sensors through creation of a joint venture
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: English ...
mehr
Vorherige115116117118119120121122123124Nächste